«

»

Covid Vaccine Equity, G20 And Moderna

Between the failure at G20 and Moderna's exclusive patent claim—ignoring NIH's role and public funding—it's been a bad week for vaccine equity.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive